8-K: Select Medical to Go Private in $3.9B Consortium Deal

Select Medical Holdings Corporation announced a definitive agreement to be acquired by a consortium led by its executive chairman, co-founder, and WCAS for $16.50 per share in cash, valuing the company at $3.9 billion.

Summary

• Select Medical Holdings Corporation (SEM) has entered into a definitive merger agreement with Stallion Intermediate Corporation and Stallion MergerSub Corporation, an entity affiliated with a consortium led by Robert A. Ortenzio (Executive Chairman, Co-Founder, and Director of Select Medical), Martin F. Jackson (Senior Executive Vice President of Strategic Finance and Operations), and Welsh, Carson, Anderson & Stowe (WCAS).
• The consortium will acquire all outstanding shares of Select Medical common stock not already owned by them for $16.50 per share in cash.
• The transaction represents an enterprise value of $3.9 billion.
• The Merger Consideration of $16.50 per share represents a premium of approximately 18% over Select Medical's unaffected share price as of November 24, 2025, and a premium of approximately 25% over its 90-day volume-weighted average closing share price for the period ending on that date.
• Robert A. Ortenzio, Martin F. Jackson, and certain of their affiliates (initial Rollover Participants), who collectively beneficially own approximately 11.8% of the outstanding shares, have agreed to roll over their equity into the parent entity of the surviving corporation instead of receiving cash.
• A special committee of disinterested and independent directors unanimously determined that the merger terms are advisable, fair to, and in the best interests of the unaffiliated stockholders, and recommended Board approval.
• The disinterested members of the Board, acting upon the Special Committee's recommendation, unanimously approved the merger agreement.
• The merger is subject to customary closing conditions, including approval by a majority of the votes cast by unaffiliated stockholders, expiration or termination of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and receipt of certain other required regulatory approvals.
• The merger is not subject to a financing condition.
• Upon completion, Select Medical will become a privately held company, and its shares of common stock will be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive for unaffiliated shareholders due to the significant premium offered and the unanimous recommendation by an independent special committee, indicating a fair valuation and a clear path to closing without a financing contingency.

Positives

• Unaffiliated stockholders will receive a cash premium of approximately 18% over Select Medical's unaffected share price as of November 24, 2025.
• The cash consideration also represents a premium of approximately 25% over Select Medical's 90-day volume-weighted average closing share price for the period ending November 24, 2025.
• The Special Committee, comprised of disinterested and independent directors, unanimously recommended the merger, indicating a fair process and outcome for unaffiliated stockholders.
• The merger is not subject to a financing condition, reducing uncertainty regarding the deal's completion.
• Select Medical's current management is expected to remain in place, ensuring operational continuity post-merger.
• Existing indebtedness is expected to remain outstanding, as the Consortium members qualify as 'Permitted Holders' under current debt documentation, simplifying the financing structure.

Negatives

• Select Medical will become a privately held company, leading to the delisting of its shares from the NYSE and deregistration under the Exchange Act, removing public trading access for current shareholders.
• The Company is required to pay Parent a termination fee of $66,504,813 in cash under certain circumstances, including if it terminates the agreement to enter into a definitive agreement for a superior proposal.
• Parent is required to pay the Company a termination fee of $133,009,627 in cash if Parent fails to timely close the Merger after the satisfaction or waiver of certain closing conditions and the Company stands ready to close.

Risks

• The inability to consummate the proposed Merger within the anticipated time period, or at all, due to reasons such as the failure to obtain required stockholder approval, regulatory approvals, or to satisfy other closing conditions.
• The risk that the Merger may be terminated in circumstances requiring Select Medical to pay a termination fee.
• The proposed Merger could disrupt Select Medical's current plans and operations or divert management's attention from its ongoing business.
• The announcement or pendency of the proposed Merger may affect Select Medical's ability to retain and hire key personnel and maintain relationships with business partners.
• The announcement or pendency of the proposed Merger could impact Select Medical's operating results and business generally.
• Significant costs, fees, and expenses are related to the proposed Merger.
• Select Medical's stock price may decline significantly if the proposed Merger is not consummated.
• The nature, cost, and outcome of any litigation and other legal proceedings, including those related to the proposed Merger and instituted against Select Medical and/or their respective directors, executive officers or other related persons.
• Other risks that could affect Select Medical's business, financial condition, or results of operations, including those set forth in the Company's most recent Annual Report on Form 10-K and any subsequent filings.
• Other risks to the consummation of the proposed Merger.

Future Outlook

The merger is expected to close mid-2026, subject to customary closing conditions including stockholder and regulatory approvals. Select Medical will continue normal operations, and current management is expected to remain in place. Upon completion, the company will become privately held, delisted from the NYSE, and deregistered from the SEC.

Management Comments

• "Select Medical will continue to operate as usual during the pendency of the Merger, with the same commitment to its patients, employees and partners."
• "Select Medical's current management is expected to remain in place following the completion of the Merger."

Industry Context

StockSavvy.ai notes that this take-private transaction in the healthcare sector, led by existing management and a private equity firm (WCAS), reflects a broader trend of private capital seeking stable, cash-generating assets, particularly in specialized healthcare services like critical illness recovery and rehabilitation. The premium offered suggests a belief in the company's intrinsic value and future growth potential, potentially shielded from public market volatility and short-term pressures.

Comparison to Industry Standards

• The 18% premium over the unaffected share price and 25% over the 90-day volume-weighted average price is generally considered a solid premium for a take-private transaction in the healthcare services sector.
• Recent take-private deals in healthcare have seen premiums ranging from 15% to 30%, such as the acquisition of Mednax (now Pediatrix Medical Group) by a private equity firm, or the acquisition of Change Healthcare by UnitedHealth Group, though the latter faced significant antitrust scrutiny.
• The enterprise value of $3.9 billion for Select Medical, a diversified operator of critical illness recovery hospitals, rehabilitation hospitals, and outpatient clinics, aligns with valuations seen for companies with established market positions and consistent cash flows in specialized healthcare segments.

Management Changes

Corporate Governance

Legal Proceedings

• The filing notes the risk of litigation related to the merger, including any such proceedings instituted against Select Medical and/or their respective directors, executive officers or other related persons.
• The Company has agreed to notify Parent of any such 'Transaction Litigation', keep Parent informed, and allow Parent to participate in the defense and settlement, with Company unable to settle without Parent's prior written consent.

Related Party Transactions

• The acquiring consortium is led by Robert A. Ortenzio (Executive Chairman, Co-Founder, and Director of Select Medical) and Martin F. Jackson (Senior Executive Vice President of Strategic Finance and Operations of Select Medical), along with Welsh, Carson, Anderson & Stowe (WCAS).
• Mr. Ortenzio, Mr. Jackson, and certain affiliates (initial Rollover Participants) will roll over their equity (approximately 11.8% of outstanding shares) into the parent entity instead of receiving cash.
• Other members of management and the Board (excluding Special Committee members) may also be invited to roll over their equity.

Stakeholder Impact

• **Shareholders (Unaffiliated)**: Will receive $16.50 per share in cash, representing a significant premium, but will lose their investment in a publicly traded company.
• **Shareholders (Rollover Participants)**: Will exchange their shares for equity in the new private parent entity, maintaining an ownership stake in the company post-merger.
• **Employees**: Current management is expected to remain in place, suggesting continuity for employees. Employee benefits for U.S. employees are guaranteed to be no less favorable for one year post-closing, with certain waivers and service credits for benefit plans.
• **Patients and Partners**: Select Medical commits to operating as usual with the same commitment to patients, employees, and partners during the merger pendency.
• **Creditors**: Existing indebtedness is expected to remain outstanding, and the acquiring entities qualify as 'Permitted Holders' under existing debt documents, suggesting minimal immediate impact on creditors.

Next Steps

• Select Medical will prepare and file a proxy statement (Schedule 14A) with the SEC.
• Select Medical and certain affiliates will jointly prepare and file a transaction statement on Schedule 13E-3 with the SEC.
• A special meeting of stockholders will be convened to obtain the Requisite Company Stockholder Approvals.
• Expiration or termination of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
• Receipt of certain other required regulatory approvals.
• The merger is expected to close mid-2026.
• Upon completion, Select Medical shares will be delisted from the NYSE and deregistered under the Exchange Act.

Key Dates

Recommendation

The proposed acquisition offers a substantial cash premium (18% over unaffected price, 25% over 90-day VWAP) to unaffiliated shareholders, making it an attractive exit opportunity. The unanimous recommendation by an independent Special Committee, coupled with the absence of a financing condition, significantly de-risks the transaction. While regulatory approvals are still pending, the involvement of existing management and a private equity firm with a clear financing structure suggests a high probability of successful completion. Investors should consider buying to capture the premium, assuming the deal closes as expected.

Keywords

Select Medical, SEM, Merger, Acquisition, Private Equity, Healthcare, WCAS, Robert A. Ortenzio, Martin F. Jackson, Go Private, Delisting, 8-K, SEC Filing, Stockholder Approval, Premium, Consortium